CHRNA4 and cancer: The regulatory role of heteromeric (α3β2α5) and homomeric (α7) nAChRs in normal and cancer (A549 or H1299) bronchial cells was studied in [35] with the use of gene-silencing method and some nAChR ligands including α-conotoxin MII (Table 1), the antagonist of α3β2 receptor subtype.